Hologic has completed its transition from a Nasdaq-listed company to a privately held entity, following the close of its $18.3 billion acquisition by Blackstone and TPG. The deal brings fresh capital and strategic backing to one of the world's foremost companies dedicated to advancing women's health.
In one of the most consequential healthcare deals of the decade, Hologic, Inc. has officially transitioned from a publicly traded company to a privately held entity. On April 7, 2026, funds managed by private equity titans Blackstone and TPG formally completed their acquisition of the Marlborough, Massachusetts-based women's health company, ending Hologic's tenure on the Nasdaq after years of steady growth and innovation in medical diagnostics and devices.
The deal — valued at up to $79 per share and representing an enterprise value of approximately $18.3 billion — stands as one of the largest leveraged buyouts in the medical technology sector in recent years. Hologic shareholders are entitled to receive $76 per share in cash, plus a non-tradable contingent value right (CVR) of up to $3 per share, payable in two equal installments of up to $1.50 each, contingent on the company achieving certain revenue milestones post-acquisition. The total consideration represents a 46% premium over Hologic's closing stock price on the last trading day prior to media reports of a possible transaction — a significant windfall for long-term investors.
Accompanying the deal closure is a significant leadership transition. José (Joe) E. Almeida, a seasoned MedTech executive, has been appointed as Hologic's new Chief Executive Officer, effective immediately. He succeeds Stephen MacMillan, who served as Chairman, President, and CEO for more than 12 years and oversaw a period of substantial transformation at the company — including Hologic's pivotal role in COVID-19 diagnostics during the pandemic. MacMillan's retirement marks the end of a defining era for the organization.
Almeida expressed confidence in the road ahead: "With the backing of Blackstone and TPG, we are poised to take the organization to new heights, with a renewed sense of purpose and greater resources to invest in innovation and initiatives that will advance the mission of enabling healthier lives around the world."
Beyond Blackstone and TPG as the primary acquirers, the transaction includes significant minority investments from two of the world's most influential sovereign wealth funds — a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of GIC, Singapore's sovereign wealth fund. Their participation signals broad global confidence in Hologic's long-term value proposition. The debt financing was committed by a consortium of major financial institutions including Citi, Bank of America, Barclays, Royal Bank of Canada, and SMBC.
The transaction was originally announced on October 21, 2025, and received stockholder approval on February 5, 2026, before formally closing on April 7, 2026. With the acquisition complete, Hologic's common stock has been delisted from the Nasdaq. The company will, however, retain its headquarters in Marlborough, Massachusetts and continue to operate under the Hologic name and brand.
The transition to private ownership is expected to afford Hologic greater operational flexibility, freeing it from quarterly earnings pressures and enabling a longer-term investment horizon. Industry observers anticipate that the backing of Blackstone and TPG will accelerate Hologic's international expansion, with particular focus on underserved markets where access to women's screening and diagnostic technologies remains critically limited.
